NEW YORK, Sept. 20 – Hybrigen and Bionomics Limited have signed a letter of intent to negotiate a partnership to study a pair of genes linked to breast cancer, the companies said on Thursday.

The target-discovery program will study the genes, TSG18 and BNO1, using genetic data identified and patented by Adelaide, Australia-based Bionomics, the firms said in a statement. For its part, Hybrigen, based in Dallas, will use its own proprietary proteomic technologies to discover drug targets that interact with those genes.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.